PIPE-791 Phase 1b Chronic Pain Trial Delivers Positive Data, Favorable Safety
CTNM has more than doubled off its 52-week low of $3.35.
Summary
Contineum Therapeutics announced positive topline Phase 1b data for its chronic pain drug candidate, PIPE-791. The study successfully met its primary endpoint, demonstrating favorable safety and tolerability, with most treatment-emergent adverse events being mild-to-moderate. Importantly, PIPE-791 showed numerically greater reductions in pain scores compared to placebo, particularly in patients with Chronic Osteoarthritis Pain (COAP), suggesting potential efficacy and functional benefits. This positive clinical update for PIPE-791 provides a significant de-risking event for the company's pipeline, especially following the previously disclosed failure of a different drug, PIPE-307, in the recent 10-K. Traders will view this as a material positive catalyst, and attention will now turn to the company's plans for advancing PIPE-791 into later-stage clinical development.
At the time of this announcement, CTNM was trading at $13.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $496.9M. The 52-week trading range was $3.35 to $16.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.